



PDAB DATA ANALYSIS REPORT: Impact of State Prescription Drug Affordability Boards on Access to Medications for Potentially Disabling Conditions – July 2024

1. Executive Summary

This report analyzes data on how state Prescription Drug Affordability Boards (PDABs) might be impacting access to medications for potentially disabling conditions, with a focus on compliance or violation of the Americans with Disabilities Act (ADA). Our findings reveal that PDABs in Colorado, Maryland, Oregon, and Washington are disproportionately targeting medications used to treat conditions highly likely or likely to be classified as disabilities under the ADA. This raises concerns about potential disparate impact and the need for PDABs to ensure their practices comply with the ADA.

2. Findings – Implications for ADA Compliance

While the intent of PDABs is to improve drug affordability, the disproportionate targeting of medications used by patients with disabilities raises concerns about potential ADA violations.

Key considerations include:

- **Disparate Impact:** PDAB practices, even if facially neutral, may disproportionately burden patients with disabilities by limiting access to necessary medications. The recent determination that Enbrel and Stelara are unaffordable in Colorado, both of which treat conditions highly likely to be considered disabilities under the ADA, raises particular concern about the potential for disparate impact on patients with disabilities.
- **Reasonable Accommodations:** PDABs must ensure their processes allow for reasonable accommodations for patients with disabilities, including access to information and opportunities for participation.

3. Data Summary

The following table summarizes the key data points from our analysis:

State	Total Drugs Eligible	HIGHLY LIKELY	LIKELY	Total Potentially Disabling	% Potentially Disabling	% HIGHLY LIKELY	% LIKELY
CO-E	343	306	28	334	97.4%	89.2	8.2
CO-S	5	3	2	5	100%	60.0	40.0
MD	8	3	5	8	100%	37.5	62.5
OR	39	24	15	39	100%	61.5	38.5
WA	188	94	68	162	86.2%	50.0	36.2



PDAB DATA ANALYSIS REPORT:

Impact of State Prescription Drug Affordability Boards on Access to Medications for Potentially Disabling Conditions – July 2024

Notes:

- Percentages are based on the total number of drugs on each state's "Possible Review" list, which represents the medications the PDAB could choose for a full affordability review.
- The Colorado data is presented in two rows to distinguish between the initial pool of drugs eligible for review and the smaller subset ultimately selected for review.
 - **CO-E (Colorado - Eligible):** This row represents the 343 drugs identified as meeting the statutory criteria for potential affordability review. This is the initial pool of medications the PDAB considers.
 - **CO-S (Colorado - Selected):** This row represents the 4 drugs chosen from the eligible pool by the PDAB for a full affordability review. This smaller subset undergoes a more detailed analysis.

4. Targeted Conditions by State

The following sections provide a categorical breakdown of the drugs selected for potential review by each state's PDAB, highlighting the primary condition categories targeted.

4.1 Colorado (343 Total Drugs PDAB Eligible)

Primary Condition Categories:

1. **Cancer (35.9%):** 123 drugs (e.g., Adcetris, Afinitor, Alecensa, etc.)
2. **Genetic Disorders (14.9%):** 51 drugs (e.g., Actimmune, Aldurazyme, Amondys 45, etc.)
3. **Autoimmune Disorders (11.4%):** 39 drugs (e.g., Acthar, Amjevita, Arcalyst, etc.)
4. **Hematological Disorders (9.6%):** 33 drugs (e.g., Adakveo, Advate, Adynovate, etc.)
5. **Cardiovascular Disorders (4.4%):** 15 drugs (e.g., Adempas, Albutein, Flolan, etc.)
6. **Endocrine Disorders (5.2%):** 18 drugs (e.g., Fensolvi, Genotropin, Glumetza, etc.)
7. **Immunodeficiency Disorders (3.5%):** 12 drugs (e.g., Asceniv, Cuvitru, Gammagard, etc.)
8. **Neurological Disorders (3.5%):** 12 drugs (e.g., Apokyn, Austedo, Diacomit, etc.)
9. **Infectious Diseases (2.6%):** 9 drugs (e.g., Ambisome, Arikayce, Avycaz, etc.)
10. **Metabolic Disorders (1.5%):** 5 drugs (e.g., Carnitor, Cholbam, Egrifta SV, etc.)
11. **Infectious Diseases - HIV (1.2%):** 4 drugs (e.g., Genvoya, Rukobia, Symtuza, etc.)
12. **Nutritional Disorders (1.2%):** 4 drugs (e.g., Elcys, Multitrac -4 Pediatric, Multitrac-4, etc.)
13. **Infectious Diseases - HCV (0.9%):** 3 drugs (e.g., Eplclusa, Harvoni, Vosevi)
14. **Sleep Disorders (0.9%):** 3 drugs (e.g., Hetlioz, Wakix, Xywav)
15. **Gastrointestinal Disorders (0.6%):** 2 drugs (e.g., Golytely, Phenohydro)
16. **Respiratory Disorders (0.6%):** 2 drugs (e.g., Esbriet, Ofec)
17. **Ophthalmic Disorders (0.6%):** 2 drugs (e.g., Ilevro, Oxervate)
18. **Wound Care (0.6%):** 2 drugs (e.g., Grafix Prime, Silvadene)
19. **Pain Management (0.3%):** 1 drug (Gelsyn-3)
20. **Hepatological Disorders (0.3%):** 1 drug (Ocaliva)
21. **Psychiatric Disorders (0.3%):** 1 drug (Dexedrine)
22. **Diagnostic Agents (0.3%):** 1 drug (Ak-Fluor)



PDAB DATA ANALYSIS REPORT:

Impact of State Prescription Drug Affordability Boards on Access to Medications for Potentially Disabling Conditions – July 2024

4.2 Maryland (8 Total Drugs Selected for Review)

Primary Condition Categories:

1. **Endocrine Disorders (50%):** 4 drugs (e.g., Farxiga, Jardiance, Ozempic, etc.)
2. **Autoimmune Disorders (12.5%):** 1 drug (Skyrizi)
3. **Respiratory Disorders (12.5%):** 1 drug (Dupixent)
4. **Psychiatric Disorders (12.5%):** 1 drug (Vyvanse)
5. **Infectious Diseases - HIV (12.5%):** 1 drug (Biktarvy)

4.3 Oregon (39 Total Drugs PDAB Eligible)

Primary Condition Categories:

1. **Autoimmune Disorders (25.6%):** 10 drugs (e.g., Cosentyx, Enbrel, Entyvio, etc.)
2. **Addictive Disorders (10.3%):** 4 drugs (e.g., Bunavail, Naloxone, Suboxone, etc.)
3. **Cancer (10.3%):** 4 drugs (e.g., Keytruda, Lenalidomide, Opdivo, etc.)
4. **Endocrine Disorders (10.3%):** 4 drugs (e.g., Ozempic, Rybelsus, Trulicity, etc.)
5. **Infectious Diseases - HIV (7.7%):** 3 drugs (e.g., Biktarvy, Genvoya, Triumeq)
6. **Respiratory Disorders (7.7%):** 3 drugs (e.g., Albuterol Sulfate, Symbicort, Dupixent)
7. **Cardiovascular Disorders (5.1%):** 2 drugs (e.g., Eliquis, Xarelto)
8. **Infectious Diseases - HCV (2.6%):** 1 drug (Mavyret)
9. **Infectious Diseases (2.6%):** 1 drug (Shingrix)
10. **Gastrointestinal Disorders (2.6%):** 1 drug (Creon)
11. **Genetic Disorders (2.6%):** 1 drug (Trikafta)
12. **Hematological Disorders (2.6%):** 1 drug (Hemlibra)
13. **Immunodeficiency Disorders (2.6%):** 1 drug (Gammagard)
14. **Neurological Disorders (2.6%):** 1 drug (Botox)
15. **Ophthalmic Disorders (2.6%):** 1 drug (Eylea)
16. **Psychiatric Disorders (2.6%):** 1 drug (Vyvanse)

4.4 Washington (188 Total Drugs PDAB Eligible)

Primary Condition Categories:

1. **Autoimmune Disorders (15.4%):** 29 drugs (e.g., Actemra, Acthar Gel, Active Injection Kit, etc.)
2. **Cancer (12.8%):** 24 drugs (e.g., Afinitor, Afinitor Disperz, Alimta, etc.)
3. **Neurological Disorders (11.2%):** 21 drugs (e.g., Aptiom, Briviact, Dantrium, etc.)
4. **Endocrine Disorders (11.2%):** 21 drugs (e.g., Caverject Impulse, Demser, Dibenzylina, etc.)
5. **Gastrointestinal Disorders (8.0%):** 15 drugs (e.g., Aciphex DR, Aciphex Sprinkle DR, Creon DR, etc.)
6. **Infectious Diseases (7.4%):** 14 drugs (e.g., Acticlate, Ambisome, Ancobon, etc.)
7. **Cardiovascular Disorders (7.4%):** 14 drugs (e.g., Betapace, Betapace AF, Coreg CR, etc.)
8. **Psychiatric Disorders (5.3%):** 10 drugs (e.g., Abilify, Anafranil, Aplenzin ER, etc.)



PDAB DATA ANALYSIS REPORT:

Impact of State Prescription Drug Affordability Boards on Access to Medications for Potentially Disabling Conditions – July 2024

9. **Pain Management (4.3%):** 8 drugs (e.g., Fentora, Lidoderm, Nalocet, etc.)
10. **Metabolic Disorders (2.7%):** 5 drugs (e.g., Cholibam, Contrave ER, Cuprimine, etc.)
11. **Hematological Disorders (2.7%):** 5 drugs (e.g., Granix, Koate, Neulasta Onpro, etc.)
12. **Dermatological Disorders (2.1%):** 4 drugs (e.g., Absorica, Claravis, Fabior, etc.)
13. **Infectious Diseases - HCV (2.1%):** 4 drugs (e.g., Epclusa, Harvoni, Pegasys, etc.)
14. **Respiratory Disorders (1.6%):** 3 drugs (e.g., Nucala, Pulmicort, Tudorza Pressair)
15. **Immunodeficiency Disorders (1.1%):** 2 drugs (e.g., Gammagard S-D, Hizentra)
16. **Infectious Diseases - HIV (1.1%):** 2 drugs (e.g., Isentress, Selzentry)
17. **Sleep Disorders (1.1%):** 2 drugs (e.g., Lunesta, Provigil)
18. **Ophthalmic Disorders (0.5%):** 1 drug (Eylea)
19. **Dental Disorders (0.5%):** 1 drug (Prevident)
20. **Toxicological Conditions (0.5%):** 1 drug (Protopam Chloride)
21. **Renal Disorders (0.5%):** 1 drug (Renvela)
22. **Urological Disorders (0.5%):** 1 drug (Uretron D-S)

4.5 Condition Categories

Across all states, the most frequently targeted condition categories include:

- **Cancer:** A primary focus in Colorado (35.9%) and a secondary focus in Oregon and Washington.
- **Genetic Disorders:** A primary focus in Colorado (14.9%) and a secondary focus in Oregon.
- **Autoimmune Disorders:** A primary focus in Colorado (11.4%) and Oregon (25.6%) and a secondary focus in Maryland and Washington.
- **Endocrine Disorders:** A primary focus in Maryland (50%) and Oregon (10.3%) and a secondary focus in Colorado and Washington.

These categories encompass numerous conditions with a high likelihood of being classified as disabilities under the ADA.

4.6 State-Specific Observations

- **Colorado:** The PDAB's broad selection criteria capture a vast number of drugs (343), with a strong emphasis on high-cost specialty medications.
 - Furthermore, the Colorado PDAB has already conducted affordability reviews on five drugs from this pool: Enbrel, Trikafta, Genvoya, Cosentyx, and Stelara. The Board determined that Trikafta and Genvoya were “not unaffordable” after concentrated patient and program advocacy, but found Enbrel, Cosentyx, and Stelara to be unaffordable, potentially leading to the establishment of Upper Payment Limits (UPLs) on these medications.



PDAB DATA ANALYSIS REPORT:

Impact of State Prescription Drug Affordability Boards on Access to Medications for Potentially Disabling Conditions – July 2024

- **Maryland:** The focus on a smaller number of drugs (8) allows for a more in-depth review process. However, the selection criteria might benefit from greater transparency.
- **Oregon:** The inclusion of "Addictive Disorders" as a primary focus highlights the PDAB's consideration of social determinants of health alongside disability.
- **Washington:** The wide range of targeted conditions, including neurological, gastrointestinal, and psychiatric disorders, demonstrates the PDAB's broad reach.

Editor's Note: Oregon and Washington's PDAB statutes contain what's often referred to as a "rare disease carve out". Those medications with rare disease indications cannot be considered for "affordability review".

5. Methodology

We examined publicly available data from states with active PDABs: Colorado, Maryland, Oregon, and Washington. We focused on the drug selection process, analyzing lists of medications identified for potential review or subject to upper payment limits (UPLs).

Key steps included:

- **Data Collection:** Compiling drug lists from each state's PDAB.
- **Condition Identification:** Cross-referencing drug lists with medical databases to identify treated conditions.
- **Disability Assessment:** Evaluating each condition's potential to be classified as a disability under the ADA using a four-tiered ranking system:
 - **HIGHLY LIKELY:** The condition is highly likely to be considered a disability under the ADA.
 - **LIKELY:** The condition could be considered a disability under the ADA depending on severity and impact on daily life.
 - **UNLIKELY:** The condition is less likely to be considered a disability under the ADA, but individual cases may qualify.
 - **VERY UNLIKELY:** The condition is very unlikely to be considered a disability under the ADA.



PDAB DATA ANALYSIS REPORT:

Impact of State Prescription Drug Affordability Boards on Access to Medications for Potentially Disabling Conditions – July 2024

6. Targeted Conditions by State - Full Drug List

Colorado (343 Total Drugs PDAB Eligible)

Primary Condition Categories:

- **Cancer (35.9%):** 123 drugs
 - Adcetris, Afinitor, Alecensa, Alunbrig, Alymsys, Ayvakit, Balversa, Bavencio, Besponsa, Blenrep, Blincyto, Bosulif, Braftovi, Brukinsa, Cabometyx, Calquence, Caprelsa, Copiktra, Cotellic, Cyramza, Darzalex, Darzalex Faspro, Daurismo, Detectnet, Empliciti, Enhertu, Erbitux, Erivedge, Erleada, Farydak, Folutyn, Fotivda, Gilotrif, Gleevec, Herzuma, Hycamtin, Ibrance, Iclusig, Idhifa, Imbruvica, Imfinzi, Imlygic, Inlyta, Inrebic, Jakafi, Jynarque, Kadcyla, Kanjinti, Keytruda, Kisqali, Kisqali Femara Co-Pack, Kyprolis, Lenvima, Libtayo, Lorbrema, Lumakras, Lutathera, Lynparza, Marqibo, Mektovi, Monjuvi, Mvasi, Nerlynx, Ninlaro, Nubeqa, Odomzo, Ogivri, Oncaspar, Ontruzant, Onureg, Opdivo, Padcev, Pemazyre, Perjeta, Piqray, Pomalyst, Poteligeo, Provence, Qinlock, Retevmo, Revlimid, Rozlytrek, Rubraca, Rydapt, Sarclisa, Scemblix, Sprycel, Sutent, Sylvant, Tabrecta, Tafinlar, Tagrisso, Talzena, Targretin, Tassigna, Tazverik, Tecentriq, Tepmetko, Treanda, Trelstar, Trisenox, Trodelvy, Truseltiq, Truxima, Tukysa, Turalio, Tykerb, Vectibix, Venclexta, Verzenio, Vitrakvi, Welireg, Xalkori, Xofigo, Xospata, Xpovio, Xtandi, Yervoy, Yonsa, Zejula, Zelboraf, Zydelig, Zytiga
- **Genetic Disorders (14.9%):** 51 drugs
 - Actimmune, Aldurazyme, Amondys 45, Aralast, Berinert, Bethkis, Cerdelga, Cerezyme, Cinryze, Crysvida, Cystadrops, Dojolvi, Elaprase, Elelyso, Emflaza, Evrysdi, Exondys 51, Fabrazyme, Firazyr, Galafold, Givlaari, Glassia, Haegarda, Kalydeco, Koselugo, Kuvan, Livmarli, Lumizyme, Nityr, Onpattro, Orkambi, Orladeyo, Oxlumio, Palynziq, Procysbi, Prolastin-C, Prolastin-C Liquid, Ravicti, Ruconest, Spinraza, Strensiq, Sucraid, Symdeko, Syprine, Takhzyro, Thiola EC, Trikafta, Vimizim, Vyondys 53, Zavesca, Zemaira
- **Autoimmune Disorders (11.4%):** 39 drugs
 - Acthar, Amjevita, Arcalyst, Aubagio, Avonex, Benlysta, Betaseron, Copaxone, Cosentyx, Enbrel, Enspryng, Entyvio, Gilenya, Humira, Ilaris, Ilumya, Inflectra, Kesimpta, Kevzara, Lupkynis, Mavenclad, Mayzent, Ocrevus, Olumiant, Orenzia, Plegridy, Rebif Rebidose, Renflexis, Rezurock, Rinvoq, Siliq, Simponi, Skyrizi, Stelara, Taltz, Taltz Autoinjector, Tecfidera, Tremfya, Vumerity
- **Hematological Disorders (9.6%):** 33 drugs
 - Adakveo, Advate, Adynovate, Afstyla, Alprolix, Benefix, Cablivi, Coagadex, Doptelet, Eloctate, Empaveli, Ferriprox, Hemlibra, Hemofil M, Idelvion, Jadenu, Kogenate FS, Kovaltry, Leukine, Neulasta, Novoeight, Novoseven, Nplate, Nuwiq, Oxbryta, Profilnine, Promacta, Reblozyl, Recombinate, Tavalisse, Ultomiris, Vonvendi, Xyntha
- **Endocrine Disorders (5.2%):** 18 drugs
 - Fensolvi, Genotropin, Glumetza, Isturisa, Korlym, Krystexxa, Miacalcin, Mycapssa, Norditropin, Nutropin AQ Nuspin 10, Nutropin AQ Nuspin 20, Roszet, Sandostatin Lar Depot, Semglee, Signifor Lar, Somatuline Depot, Somavert, Tepezza
- **Cardiovascular Disorders (4.4%):** 15 drugs
 - Adempas, Albutein, Flolan, Fragmin, Inderal, Letairis, Northera, Opsumit, Orenitram, Remodulin, Tracleer, Tyvaso, Upravi, Vyndamax, Vyndaqel



PDAB DATA ANALYSIS REPORT:

Impact of State Prescription Drug Affordability Boards on Access to Medications for Potentially Disabling Conditions – July 2024

- **Immunodeficiency Disorders (3.5%):** 12 drugs
 - Asceniv, Cuvitru, Gammagard, Gammagard Liquid, Gammaked, Gammalex, Gamunex-C, Hizentra, Hyqvia, Octagam, Panzyga, Xembify
- **Neurological Disorders (3.5%):** 12 drugs
 - Apokyn, Austedo, Diacomit, Fintepla, Firdapse, Ingrezza, Keveyis, Radicava, Sabril, Sympazan, Xeomin, Zonegran
- **Infectious Diseases (2.6%):** 9 drugs
 - Ambisome, Arikayce, Avycaz, Daraprim, Fetroja, Mycamine, Recarbrio, Sivextro, Teflaro
- **Metabolic Disorders (1.5%):** 5 drugs
 - Carnitor, Cholbam, Egrifta SV, Gattex, Myalept
- **Infectious Diseases - HIV (1.2%):** 4 drugs
 - Genvoya, Rukobia, Symtuza, Trogarzo
- **Nutritional Disorders (1.2%):** 4 drugs
 - Elcys, Multitrace -4 Pediatric, Multitrace-4, Tralement
- **Infectious Diseases - HCV (0.9%):** 3 drugs
 - Epclusa, Harvoni, Vosevi
- **Sleep Disorders (0.9%):** 3 drugs
 - Hetlioz, Wakix, Xywav
- **Gastrointestinal Disorders (0.6%):** 2 drugs
 - Golytely, Phenohydro
- **Respiratory Disorders (0.6%):** 2 drugs
 - Esbriet, Ofec
- **Ophthalmic Disorders (0.6%):** 2 drugs
 - Ilevro, Oxervate
- **Wound Care (0.6%):** 2 drugs
 - Grafix Prime, Silvadene
- **Pain Management (0.3%):** 1 drug
 - Gelsyn-3
- **Hepatological Disorders (0.3%):** 1 drug
 - Ocaliva
- **Psychiatric Disorders (0.3%):** 1 drug
 - Dexedrine
- **Diagnostic Agents (0.3%):** 1 drug
 - Ak-Fluor

Secondary Condition Categories:

- **Endocrine Disorders:**
 - Acthar, Afinitor, Jakafi, Truxima, Ultomiris
- **Neurological Disorders:**
 - Afinitor, Inderal, Xeomin
- **Infectious Diseases - HIV:**
 - Pomalyst, Egrifta SV



PDAB DATA ANALYSIS REPORT: Impact of State Prescription Drug Affordability Boards on Access to Medications for Potentially Disabling Conditions – July 2024

Maryland (8 Total Drugs Selected for Review)

Primary Condition Categories:

- **Endocrine Disorders (50%):** 4 drugs
 - Farxiga, Jardiance, Ozempic, Trulicity
- **Autoimmune Disorders (12.5%):** 1 drug
 - Skyrizi
- **Respiratory Disorders (12.5%):** 1 drug
 - Dupixent
- **Psychiatric Disorders (12.5%):** 1 drug
 - Vyvanse
- **Infectious Diseases - HIV (12.5%):** 1 drug
 - Biktarvy

Secondary Condition Categories:

- **Autoimmune Disorders:**
 - Dupixent
- **Cardiovascular Disorders:**
 - Farxiga, Jardiance



PDAB DATA ANALYSIS REPORT:

Impact of State Prescription Drug Affordability Boards on Access to Medications for Potentially Disabling Conditions – July 2024

Oregon (39 Total Drugs PDAB Eligible)

Primary Condition Categories:

- **Autoimmune Disorders (25.6%):** 10 drugs
 - Cosentyx, Enbrel, Entyvio, Humira, Inflectra, Ocrevus, Skyrizi, Stelara, Tremfya, Ultomiris
- **Addictive Disorders (10.3%):** 4 drugs
 - Bunavail, Naloxone, Suboxone, Zubsolv
- **Cancer (10.3%):** 4 drugs
 - Keytruda, Lenalidomide, Opdivo, Revlimid
- **Endocrine Disorders (10.3%):** 4 drugs
 - Ozempic, Rybelsus, Trulicity, Jardiance
- **Infectious Diseases - HIV (7.7%):** 3 drugs
 - Biktarvy, Genvoya, Triumeq
- **Respiratory Disorders (7.7%):** 3 drugs
 - Albuterol Sulfate, Symbicort, Dupixent
- **Cardiovascular Disorders (5.1%):** 2 drugs
 - Eliquis, Xarelto
- **Infectious Diseases - HCV (2.6%):** 1 drug
 - Mavyret
- **Infectious Diseases (2.6%):** 1 drug
 - Shingrix
- **Gastrointestinal Disorders (2.6%):** 1 drug
 - Creon
- **Genetic Disorders (2.6%):** 1 drug
 - Trikafta
- **Hematological Disorders (2.6%):** 1 drug
 - Hemlibra
- **Immunodeficiency Disorders (2.6%):** 1 drug
 - Gammagard
- **Neurological Disorders (2.6%):** 1 drug
 - Botox
- **Ophthalmic Disorders (2.6%):** 1 drug
 - Eylea
- **Psychiatric Disorders (2.6%):** 1 drug
 - Vyvanse

Secondary Condition Categories:

- **Autoimmune Disorders:**
 - Dupixent, Ultomiris
- **Cardiovascular Disorders:**
 - Jardiance



PDAB DATA ANALYSIS REPORT:

Impact of State Prescription Drug Affordability Boards on Access to Medications for Potentially Disabling Conditions – July 2024

Washington (188 Total Drugs PDAB Eligible)

Primary Condition Categories:

- **Autoimmune Disorders (15.4%):** 29 drugs
 - Actemra, Acthar Gel, Active Injection Kit, Arcalyst, Atgam, Aubagio, Azathioprine, Benlysta, Beta 1 Kit, BSP 0820 Kit, Cellcept, Cimzia, Doubledex, Enbrel, Gilenya, Humira, Kineret, Lemtrada, Orenzia, Otrexup, Plegridy, Rapamune, Rasuvo, Remicade, Simponi, Taltz, Tecfidera DR, Xeljanz, Xeljanz XR
- **Cancer (12.8%):** 24 drugs
 - Afinitor, Afinitor Disperz, Alimta, Alymsys, Cabometyx, Cometriq, Emcyt, Erivedge, Inlyta, Jevtana, Lenvima, Lysodren, Matulane, Nilandron, Odomzo, Purixan, Tafinlar, Tarceva, Truxima, Tykerb, Votrient, Xtandi, Yervoy, Zytiga
- **Neurological Disorders (11.2%):** 21 drugs
 - Aptiom, Briviact, Dantrium, Dysport, Keveyis, Lamictal, Lamictal ODT, Lamictal XR, Lodosyn, Lyrica, Mestinon, Mirapex ER, Mysoline, Primidone, Relpax, Revonto, Sabril, Tasmar, Trokendi XR, Zanaflex, Zonegran
- **Endocrine Disorders (11.2%):** 21 drugs
 - Caverject Impulse, Demser, Dibenzyline, Edex, Follistim AQ, Glumetza ER, Gonal-F, Gonal-F RFF, Gonal-F RFF Redi-Ject, Methitest, Parlodel, Pripidil, Samsca, Semglee (YFGN), Sensipar, Somatuline Depot, SPS, Stendra, Unithroid, Viagra, Yuvaferm
- **Gastrointestinal Disorders (8.0%):** 15 drugs
 - Aciphex DR, Aciphex Sprinkle DR, Creon DR, Donnatal, Gavilyte-C, Gavilyte-G, Golytely, Librax, Mytesi, Pancreaze DR, Pertzye DR, Prilosec DR, Relistor, Tigan, Viokace
- **Infectious Diseases (7.4%):** 14 drugs
 - Acticlate, Ambisome, Ancobon, Cancidas IV, Daraprim, Diflucan, Doryx DR, Eraxis, Ery-Tab DR, Monodox, Noxafil DR, Sporanox, Targadox, Valcyte
 - **Cardiovascular Disorders (7.4%):** 14 drugs
 - Betapace, Betapace AF, Coreg CR, Fragmin, Isordil Titradoso, Lovaza, Nitro-Dur, Optison, Revatio, Sular ER, Tekturna, Tekturna HCT, Vasotec, Zontivity
- **Psychiatric Disorders (5.3%):** 10 drugs
 - Abilify, Anafranil, Aplenzin ER, Desoxyn, Geodon, Invega Sustenna, Rexulti, Tranxene T-Tab, Vraylar, Wellbutrin XL
- **Pain Management (4.3%):** 8 drugs
 - Fentora, Lidoderm, Nalocet, Nucynta, Nucynta ER, Oxaydo, Percocet, Prolate
- **Metabolic Disorders (2.7%):** 5 drugs
 - Cholbam, Contrave ER, Cuprimine, Depen, Oracit
- **Hematological Disorders (2.7%):** 5 drugs
 - Granix, Koate, Neulasta Onpro, Procrit, Promacta
- **Dermatological Disorders (2.1%):** 4 drugs
 - Absorica, Claravis, Fabior, Sorilux
- **Infectious Diseases - HCV (2.1%):** 4 drugs
 - Epclusa, Harvoni, Pegasys, Sovaldi
- **Respiratory Disorders (1.6%):** 3 drugs



PDAB DATA ANALYSIS REPORT:

Impact of State Prescription Drug Affordability Boards on Access to Medications for Potentially Disabling Conditions – July 2024

- Nucala, Pulmicort, Tudorza Pressair
- **Immunodeficiency Disorders (1.1%):** 2 drugs
 - Gammagard S-D, Hizentra
- **Infectious Diseases - HIV (1.1%):** 2 drugs
 - Isentress, Selzentry
- **Sleep Disorders (1.1%):** 2 drugs
 - Lunesta, Provigil
- **Ophthalmic Disorders (0.5%):** 1 drug
 - Eylea
- **Dental Disorders (0.5%):** 1 drug
 - Prevident
- **Toxicological Conditions (0.5%):** 1 drug
 - Protopam Chloride
- **Renal Disorders (0.5%):** 1 drug
 - Renvela
- **Urological Disorders (0.5%):** 1 drug
 - Uretron D-S

Secondary Condition Categories:

- **Endocrine Disorders:**
 - Active Injection Kit, Beta 1 Kit, BSP 0820 Kit, Doubledex
- **Neurological Disorders:**
 - Afinitor, Afinitor Disperz, Inderal, Lamictal, Lamictal ODT, Lamictal XR, Lyrica
- **Autoimmune Disorders:**
 - Jakafi, Truxima, Rapamune, Remicade
- **Cancer:**
 - Active Injection Kit, Beta 1 Kit, BSP 0820 Kit, Doubledex, Rapamune
- **Dermatological Disorders:**
 - Dysport, Otrexup, Rasuvo
- **Infectious Diseases - HIV:**
 - Pomalyst, Egrifta SV